Westlake Village BioPartners
Venture capitalLos Angeles · Pre-Seed–Series A · 13 people tracked
Also known as WESTLAKE BIOPARTNERS, LLC
Find your way into Westlake Village BioPartners
3,099 people in our graph share verified history with the Westlake Village BioPartners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
The firm takes a people-first, company-creation approach to life science investing, crafting and incubating a concentrated portfolio of biotech companies around world-class entrepreneurs. Deeply embedded in the Los Angeles biotech ecosystem it helped catalyze, it is intentionally scaled to offer close, hands-on relationships with founders, guiding companies from ideation and preclinical research through clinical and commercial impact. The firm emphasizes empowering the right people, providing personal attention, capital, and access to a complementary network of innovation and community, with the goal of turning scientific breakthroughs into life-saving medicines that address the greatest unmet patient needs in California and beyond.
Source: firm website, verified Sep 15, 2026.
Team · 13 people
from the firm's website & public directories
What they invest in
from 23 of 32 portfolio companiesBiotech ×22Healthtech ×12Medical Devices ×6Digital Health ×5AI & Machine Learning ×4Deep Tech ×3Longevity ×1
HQs:United States×20
Investments · 32 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 52024 · 22023 · 12022 · 12021 · 62020 · 12019 · 12018 · 119 dated
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtechMenlo Park, US
Rekha Hemrajani(Executive Officer)inMerdad Parsey(Executive Officer, Director)inDavid Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)inMarie O'Farrell(Chief Scientific Officer)in
Board seatBeth Seidenberg· per SEC Form D · $80M raise · filed Jan 2021
Co-investorsAltium CapitalHM Venture PartnersKleiner PerkinsNew Enterprise Associates (NEA)
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementvenBio Partners+1 more
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesVida VenturesGilead SciencesKleiner PerkinsOxford Finance LLCRTW Investments L.P.+1 more
Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.
BiotechDeep TechDigital HealthMedical Devices
Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)in
Co-investorsVersant Ventures
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inLaura Norris(Executive Officer, Director)inTimothy Read(Executive Officer, Director)Eric Martin(Executive Officer)in
BoardAmit Mehta(Director)
Board seatDavid AllisonMira Chaurushiya· per SEC Form D · $35.3M raise · filed Nov 2025
Co-investorsFifty YearsFundersClubTau VenturesvenBio PartnersY CombinatorAlamo Angels+2 more
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)
BoardValentin Barsan(Director)Sean Parker(Director)
Board seatBeth Seidenberg· per SEC Form D
Co-investorsARCH Venture PartnersHitachi VenturesKleiner PerkinsOUP (Osage University Partners)SoftBank Vision Fund
HealthtechSeattle, US
John D. Hoekman(Executive Officer, Director)in
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatDavid Allison· per SEC Form D · $1.9M raise · filed Apr 2021
Co-investors5AM VenturesB Capital GroupvenBio Global StrategicvenBio Partners
.jpeg){kind=logo}
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardJim Tananbaum(Director)inDeborah Palestrant(Director)inKevin Raidy(Director)
Board seatBeth Seidenberg· per SEC Form D
Co-investorsAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi Ventures5AM Ventures
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
Board seatDavid Allison· per SEC Form D
Co-investors5AM VenturesOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalRTW Investments L.P.+1 more
BiotechSan Francisco, US
Kristine M Ball(Executive Officer, Director)inZachary Hill(Executive Officer, Director)in
BoardNisha Marathe(Director)Keno Gutierrez(Director)inDavid Morris(Director)
Board seatDavid Allison· per SEC Form D
Co-investors5AM VenturesBioGeneration VenturesRoche Venture Fund
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Board seatBeth Seidenberg· per SEC Form D · $125M raise · filed Oct 2025
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+9 more
3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
K. Christopher GarciaMarvin Gee(Founder)in
Co-investorsAsset Management CompanyCRV (Charles River Ventures)Menlo VenturesOS FundStarlight Ventures
AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.
BiotechNatick, US
Catherine Pearce(CEO & Founder)inDHSc(Founder)Justin R Thompson(Founder)in
Co-investorsVersant VenturesWestlake BioPartners
Borealis develops RNA medicines to treat kidney diseases.
BiotechDigital Health
Co-investorsVersant Ventures
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)
Co-investorsOrbiMedRA CapitalKleiner PerkinsNVIDIA
BiotechSan Diego, US
Kevin Forrest, Ph.D.(Executive Officer, Director)
BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)
Co-investorsKleiner PerkinsOsage University PartnersVersant Ventures
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsKleiner PerkinsSoftBank GroupSoftBank Vision FundACORN BIOVENTURESCowen Healthcare InvestmentsHBM Partners+1 more
Oorja Bio is a biotechnology company developing therapies focused on fibrotic disease, aiming to repair, reverse, and remodel fibrosis.
BiotechHealthtech
Sujay Kango(Chief Executive Officer & Founder)inJanethe Pena(Chief Medical Officer & Founder)inConnie Coulomb(Chief Business Officer & Founder)in
Co-investorsAndreessen HorowitzKleiner PerkinsWestlake BioPartners
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life Sciences5AM VenturesDCVC BioFrazier Healthcare Partners
Recludix Pharma operates a drug discovery platform that combines custom DNA-encoded libraries (DELs), massively parallel structure-activity relationship analysis, structure-based design, and a family-wide SH2 domain screening panel.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
Nancy Whiting(CEO)in
Co-investorsAccess BiotechnologyNew Enterprise Associates (NEA)
Vedana Therapeutics develops next-generation biologic medicines for migraine prevention, targeting PACAP and CGRP-independent pathways to address unmet needs in patients inadequately controlled by current therapies.
BiotechHealthtechMedical Devices
Co-investorsCanaan Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AllRockArsenalCinCor PharmaElectraExpansion TherapeuticsKateLatigoMagnetic InsightStarTmunityVega
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
3 IPOsSagimet BiosciencesNASDAQ: SGMTAlumisNASDAQ: ALMSKyverna TherapeuticsNASDAQ: KYTX
Portfolio news
latest coverage across their companies
Latigo Bio · labusinessjournal.com · Aug 17, 2026
Alumis · stocktitan.net · Aug 13, 2026
Electra Therapeutics · geekwire.com · Jul 13, 2026
Oorja Bio · houston.innovationmap.com · Jun 9, 2026
Recludix · briefglance.com · Mar 16, 2026
Star Therapeutics · pharmaceutical-technology.com · Oct 1, 2025
CinCor Pharma · bizjournals.com · Sep 18, 2025
Frequently asked questions
- How many investments has Westlake Village BioPartners made?
- Westlake Village BioPartners has 32 tracked investments, 3 of which have exited, including 7 dated in the last 24 months.
- What stage does Westlake Village BioPartners invest at?
- Westlake Village BioPartners invests at the Pre-Seed, Seed, Series A stages.
- What is Westlake Village BioPartners's typical check size?
- Westlake Village BioPartners typically writes checks of $100K – $5M.
- What sectors does Westlake Village BioPartners focus on?
- Westlake Village BioPartners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Westlake Village BioPartners located?
- Westlake Village BioPartners is headquartered in Los Angeles, US.
- Does Westlake Village BioPartners lead rounds?
- Westlake Village BioPartners typically participates in rounds rather than leading them.
- Who does Westlake Village BioPartners co-invest with?
- Westlake Village BioPartners most often shares deals with Kleiner Perkins, OrbiMed, SoftBank Vision Fund, among 19 tracked co-investors.
Media · Podcasts & interviews
featuring the teamSean Harper -- Westlake Village BioPartners
LA Venture · Sean Harper
Images
Co-investors · 13
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Celesta Capital is a venture capital firm that invests in deep tech companies at the forefront of science and engineering.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
BioGeneration Ventures is a venture capital firm that invests in early-stage biotech companies in Europe, with a focus on healthcare innovations.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
▶1 more co-investors
Firms observed investing alongside Westlake Village BioPartners, from public investor directories. Shared companies are the overlap with Westlake Village BioPartners's recorded portfolio.
Similar investors
Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
InnoCom Bio Equities manages life science special purpose vehicles, offering investors a diversified portfolio of innovative life sciences technologies and providing seed capital to innovators and founders.
CABHI (Centre for Aging + Brain Health Innovation) is a pan-Canadian organization that funds and supports researchers, innovators, and startups working on brain health and aging solutions, and helps healthcare and community organizations adopt them.